None listed
Conditions
Interventions
None listed
Sponsors
Ferring pharmaceuticals Korea
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. South Korean female patients who received controlled ovarian hyperstimulation for assisted reproductive technology procedures such as IVF or ICSI from January 2013 to December 2017. 2. Women between the ages of 18 and 40 years at the time of controlled ovarian hyperstimulation. 3. The first controlled ovarian hyperstimulation cycle. 4. Body mass index between 17.5 and 32.0 kg/m2 (both inclusive). 5. Subjects who received the procedure using a GnRH antagonist cycle. 6. Subjects who received rFSH only. 7. Controlled ovarian hyperstimulation cycle = 20 days. 8. Regular menstrual cycles of 24–35 days (both inclusive), presumed to be ovulatory. 9. AMH levels available within 1 year prior to controlled ovarian hyperstimulation.
Exclusion criteria
Exclusion criteria: 1. Known endometriosis stage III–IV. 2. Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy and before week 24 of pregnancy). 3. Any known clinically significant systemic disease (e.g., insulin-dependent diabetes). 4. Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events. 5. Any known endocrine or metabolic abnormalities. 6. Known moderate or severe impairment of renal or hepatic function. 7. Use of any rFSH preparations during the last 3 months before controlled ovarian hyperstimulation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate at 10~11 weeks, % | — |
Secondary
| Measure | Time frame |
|---|---|
| Live birth rates, The number of retrieved oocytes, The number of mature oocytes;Incidence rate of Ovarian Hyperstimulation Syndrome %, Hospitalization due to Ovarian Hyperstimulation Syndrome) | — |
Countries
Korea, Republic of
Contacts
Public ContactYoung-Mi Jeon
Chung-Ang Univerisity Hospital
Outcome results
None listed